Jounce Therapeutics

General Information

We are a clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Through the use of our Translational Science Platform, we first focus on specific cell types within tumors to prioritize targets, and then identify related biomarkers designed to match the right therapy to the right patient. Our strategy is to create immunotherapies targeting a variety of the diverse cellular components of the immune system, as well as non-immune cells resident within the tumor, all of which can vary greatly among tumors within and across indications.

Employees: 85
Founded: 2012
Contact Information
Address 1030 Massachusetts Avenue, Cambridge, MA 02138 , US
Phone Number (857) 259-3840
Web Address
View Prospectus: Jounce Therapeutics
Financial Information
Market Cap $422.3mil
Revenues $16.9 mil (last 12 months)
Net Income $-29.3 mil (last 12 months)
IPO Profile
Symbol JNCE
Exchange NASDAQ
Shares (millions): 6.5
Price range $16.00 - $16.00
Est. $ Volume $104.0 mil
Manager / Joint Managers J.P. Morgan/ Cowen and Company
CO-Managers Wells Fargo Securities/ Baird
Expected To Trade: 1/27/2017
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change